- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00608725
Pathophysiology of Orthostatic Intolerance
September 20, 2023 updated by: Satish R. Raj
The purpose of this study is to describe the mechanism of orthostatic intolerance, relying on cardiovascular physiological studies.
The syndrome is of undetermined etiology, but the syndrome causes impairment of a number of young adults, females more than males, with symptoms of tachycardia, fatigue, lightheadedness, palpitations, blurred vision, chest discomfort, difficulty concentrating, and dizziness with the upright posture.
It is believed that many different pathophysiological processes can give rise to this disorder.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Bonnie K Black, BSN CNP
- Phone Number: 615-343-6499
- Email: rajlab@vumc.org
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Recruiting
- Vanderbilt University
-
Principal Investigator:
- David Robertson, M.D.
-
Sub-Investigator:
- Satish R Raj, MD MSCI
-
Sub-Investigator:
- Italo Biaggioni, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Orthostatic intolerance
Exclusion Criteria:
- Inability or unwillingness to give informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Patients
Patients with orthostatic intolerance
|
131-I-Human Serum Albumin Blood Volume Assessment Kit
Other Names:
Quantitative Sweat Testing
Other Names:
Atropine 0.04 mg/kg IV in divided doses Propranolol 0.2 mg/kg IV in divided doses
Other Names:
|
Other: Healthy Control Subjects
Healthy subjects to determine "normal" response
|
131-I-Human Serum Albumin Blood Volume Assessment Kit
Other Names:
Quantitative Sweat Testing
Other Names:
Atropine 0.04 mg/kg IV in divided doses Propranolol 0.2 mg/kg IV in divided doses
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Physiological abnormalities in orthostatic intolerance
Time Frame: 1 day
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
quantitative sweat testing
Time Frame: 2 hours
|
2 hours
|
blood volume
Time Frame: 1 day
|
1 day
|
intrinsic heart rate
Time Frame: 1 hour
|
1 hour
|
residual sympathetic function after pharmacological autonomic blockade
Time Frame: 3 hours
|
3 hours
|
norepinephrine spillover
Time Frame: 3 hours
|
3 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: David Robertson, MD, Vanderbilt University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 1996
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
January 22, 2008
First Submitted That Met QC Criteria
February 5, 2008
First Posted (Estimated)
February 6, 2008
Study Record Updates
Last Update Posted (Actual)
September 21, 2023
Last Update Submitted That Met QC Criteria
September 20, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Arrhythmias, Cardiac
- Cardiac Conduction System Disease
- Autonomic Nervous System Diseases
- Primary Dysautonomias
- Tachycardia
- Postural Orthostatic Tachycardia Syndrome
- Orthostatic Intolerance
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Vasodilator Agents
- Propranolol
Other Study ID Numbers
- 8398
- NIH HL56693
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tachycardia
-
Erasmus Medical CenterUnknownTachycardia, Supraventricular | Tachycardia; Paroxysmal, SupraventricularNetherlands
-
Medtronic Cardiac Rhythm and Heart FailureCompletedHeart Disease | Supraventricular Tachycardia | AtrioVentricular Nodal Reentrant TachycardiaUnited States, Canada
-
University of PretoriaCompletedSupra-ventricular TachycardiaSouth Africa
-
Milestone Pharmaceuticals Inc.Medpace, Inc.CompletedParoxysmal Supraventricular Tachycardia (PSVT)United States, Canada
-
Milestone Pharmaceuticals Inc.TerminatedParoxysmal Supraventricular Tachycardia (PSVT)United States
-
University Hospital, ToulouseRecruitingSupraventricular Tachycardia | Atrioventricular Nodal Reentry TachycardiaFrance
-
Princess Margaret Hospital, Hong KongUnknownSupraventricular Tachycardia | Atrioventricular Nodal Reentrant TachycardiaChina
-
University Hospital of FerraraRecruitingAtrioventricular Nodal Re Entrant TachycardiaItaly
-
Parc de Salut MarCompletedSupraventricular Tachycardia | Atrioventricular Nodal Re Entrant TachycardiaSpain
-
Milestone Pharmaceuticals Inc.RecruitingParoxysmal Supraventricular TachycardiaUnited States
Clinical Trials on DAXOR
-
Medical University of South CarolinaMedtronicCompletedCongestive Heart FailureUnited States
-
Duke UniversityDaxor CorporationCompleted
-
NYU Langone HealthDaxor CorporationTerminatedHeart FailureUnited States
-
Uniformed Services University of the Health SciencesDuke University; Henry M. Jackson Foundation for the Advancement of Military...UnknownHypovolemia | Hypervolemia
-
Virginia Commonwealth UniversityDaxor CorporationWithdrawn
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)CompletedPostural Orthostatic Tachycardia SyndromeUnited States
-
Vanderbilt UniversityNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedPostural Orthostatic Tachycardia SyndromeUnited States
-
Vanderbilt University Medical CenterUniversity of OklahomaEnrolling by invitationCardiovascular Diseases | Arrhythmias, Cardiac | Autonomic Nervous System Diseases | Primary Dysautonomias | Tachycardia | Orthostatic Intolerance | Postural Tachycardia Syndrome | Postural Orthostatic Tachycardia SyndromeUnited States